SUBSCRIBE: Print / Digital / eNewsletter
Fidaxomicin (Dificid, Merck) is indicated in adults and pediatric patients aged 6 months and older for the treatment of Clostridioides difficile-associated diarrhea.
Pfizer announced the introduction of 3 new oncology biosimilars to the US market at a substantially discounted price.
Lefamulin was approved by the FDA in August 2019 for the treatment of CABP.
FDA approval decision expected in the second quarter of 2020.
Solriamfetol (Sunosi, Jazz Pharmaceuticals) to treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea was approved on March 20, 2019.
The FDA has approved semaglutide (Ozempic, Novo Nordisk) for the reduction of major adverse cardiovascular (CV) events in patients with type 2 diabetes and established CV disease.
Novavax’s recombinant quadrivalent flu vaccine candidate (NanoFlu) is being evaluated in an ongoing phase 3 clinical study for use in older adults.
Here are the top drugs expected to be approved this year.
Viaskin Peanut (DBV Technologies) achieved durable, long-term clinical benefit in peanut-allergic children.
AstraZeneca’s supplemental New Drug Application for dapagliflozin (Farxiga) has been granted Priority Review by the FDA.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
